Gilead Sciences (NASDAQ:GILD) Price Target Raised to $110.00 at Piper Sandler

Gilead Sciences (NASDAQ:GILD) had its price target increased by Piper Sandler from $105.00 to $110.00 in a research report report published on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on GILD. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Robert W. Baird raised their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Citigroup started coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target for the company. Finally, Wolfe Research began coverage on Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price target on the stock. Eleven research analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.33.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $103.31 on Wednesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market cap of $128.75 billion, a P/E ratio of 1,147.89, a P/E/G ratio of 1.25 and a beta of 0.18. The firm’s 50 day moving average price is $93.14 and its 200-day moving average price is $87.12. Gilead Sciences has a one year low of $62.07 and a one year high of $104.71.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. As a group, equities research analysts predict that Gilead Sciences will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 3.06%. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 572,824 shares of company stock worth $53,611,715 in the last three months. Insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $25,000. HHM Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the last quarter. Valued Wealth Advisors LLC grew its stake in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares during the period. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $28,000. Finally, Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the 4th quarter worth about $29,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.